KALA (KALA BIO, Inc. Common Stock) Stock Analysis - News
KALA BIO, Inc. Common Stock (KALA) is a publicly traded Healthcare sector company. As of May 21, 2026, KALA trades at $2.67 with a market cap of $50.38M and a P/E ratio of -0.82. KALA moved +4.35% today. Year to date, KALA is -91.40%; over the trailing twelve months it is -98.66%. Its 52-week range spans $2.52 to $1,030.00. Rallies surfaces KALA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in KALA news today?
Kala Bio Initiates 1-for-50 Reverse Split, Reduces Shares Outstanding to 18.6M: KALA BIO will execute a 1-for-50 reverse stock split effective May 8, 2026, with split-adjusted trading beginning May 11 on the Nasdaq Capital Market. The split reduces outstanding shares from 929,491,578 to about 18,589,832, with fractional shareholders receiving cash based on the May 7 closing price.
Iwicki Mark T sold 154.89K (~$125.46K) on Oct 23, 2025.
Reumuth Mary sold 967 (~$792.94) on Oct 23, 2025.
Reumuth Mary sold 32.23K (~$26.75K) on Oct 22, 2025.
KALA Analyst Consensus
KALA analyst coverage data. Average price target: $0.00.
Common questions about KALA
What changed in KALA news today?
Kala Bio Initiates 1-for-50 Reverse Split, Reduces Shares Outstanding to 18.6M: KALA BIO will execute a 1-for-50 reverse stock split effective May 8, 2026, with split-adjusted trading beginning May 11 on the Nasdaq Capital Market. The split reduces outstanding shares from 929,491,578 to about 18,589,832, with fractional shareholders receiving cash based on the May 7 closing price.
Does Rallies summarize KALA news?
Yes. Rallies summarizes KALA news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is KALA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for KALA. It does not provide personalized investment advice.
